ProEx™ C - a new molecular biomarker assay

ProEx™ C is a new biomarker assay to identify cervical cancer. It has been developed by TriPath Imaging, Inc and uses the fact that specific proteins are expressed when cervical cancer is present. These proteins may be identified and quantified using a cocktail of highly specific molecular biomarkers.

Unlike HPV tests, this diagnostic test is specific for cervical cancer disease (CIN2+) and can be used as a reflex test on low grade SurePath® LBC cytology samples. A number of trials have been reported and more are underway. UK Trials have commenced.

More details are available at www.proexc.com.

ProEx™ C is a new biomarker assay to identify cervical cancer. It has been developed by Tripath Imaging, Inc and uses the fact that specific proteins are expressed when cervical cancer is present. These proteins may be identified and quantified using a cocktail of highly specific molecular biomarkers.

Unlike HPV, this diagnostic test is specific for cervical cancer disease (CIN2+) and can be used as a reflex test on low grade SurePath™ LBC cytology samples. A number of trials have been reported and more are underway.

Trials in the UK will begin shortly.

More details are available at www.tripathimaging.com or www.proexc.com